Tirzepatide and Mounjaro: is it the same medicine?

You searched 'tirzepatide' but every pharmacy lists 'Mounjaro', here is why

Pharmaceutical companies give a medicine two identities: a generic scientific name and a proprietary brand name. The generic name for this treatment is tirzepatide. Eli Lilly, the company that developed it, markets it under the brand name Mounjaro in the UK. Think of it the same way you might think of ibuprofen and Nurofen, the same molecule, different labels on the packet.

This matters in practice. When you read about the SURMOUNT clinical programme (the large trials involving thousands of adults that generated the headline weight-loss figures) the papers use 'tirzepatide'. When you look at a pharmacy listing, a private prescription or the NHS guidance at NICE's technology appraisal TA1026, you will see 'Mounjaro'. They describe the same drug. If you are weighing up whether to search for Mounjaro or tirzepatide, it helps to understand that neither term is wrong, but always check the GPhC register before ordering from any online pharmacy.

For a fuller breakdown of the science behind the molecule itself, our tirzepatide explainer covers how each receptor pathway contributes to appetite regulation and blood-sugar control.

What a dual agonist actually does, and why the name 'tirzepatide' sounds unfamiliar

Most GLP-1 medicines work on a single receptor. Tirzepatide was engineered to activate two: the GLP-1 receptor and the GIP receptor. Both are involved in how the gut signals fullness, how insulin is released after eating, and how quickly food moves through the stomach. Activating them together appears to produce a stronger appetite-suppressing effect than either pathway alone, which is reflected in the trial evidence and partly explains why NICE, in its December 2024 appraisal, noted that indirect comparisons favour tirzepatide over semaglutide.

The name 'tirzepatide' is a systematic international non-proprietary name (INN), a neutral, non-trademarked label used in regulatory documents, clinical papers and prescriptions worldwide. 'Mounjaro' is the name you will see on the box, the pen and the pharmacy listing. Both are correct. Neither is a generic 'copy' of the other; there is currently no generic tirzepatide on the UK market.

One thing worth knowing: 'Zepbound' sometimes appears in searches. That is the US brand name for tirzepatide, used by Eli Lilly in America. It does not exist as a UK product and is not available from any UK pharmacy. If you want to read more about what tirzepatide is and how it works, our dedicated page covers the molecule, its mechanism and its place in UK weight management. In Britain, tirzepatide is Mounjaro, full stop.

What arrives when you are approved (and how the pen relates to the names you have read

Once a prescriber approves a course of treatment, the item dispatched is a Mounjaro KwikPen) each pen contains four weekly doses of tirzepatide at the prescribed strength. Treatment begins at 2.5 mg, a tolerability phase that gives the body time to adjust, and is titrated upward by the prescriber in steps over subsequent weeks. The pen itself is small, pre-filled and reusable for its four doses; changing the needle weekly is the only preparation needed.

At nume, once a consultation has been clinically reviewed and approved, the pen ships the same day for next-working-day DPD delivery. It arrives in plain, unbranded packaging, you will get a tracking notification on your phone so you know the exact window. Nothing on the box identifies the contents to anyone but you.

Pricing for treatment varies by strength and provider. Eli Lilly raised its UK list prices significantly from September 2025, which affected private costs across the market. For context on what those costs cover and what to look out for in transparent pricing, our treatment page sets out what is included at nume. You can also find a detailed look at tirzepatide at the higher dose strengths, including what the titration schedule looks like and what to expect as you progress through treatment.

Tirzepatide, Mounjaro and the UK licence (who it is for

The MHRA has licensed Mounjaro (tirzepatide) in the UK for weight management alongside a reduced-calorie diet and increased physical activity, for adults with a BMI of 30 or above, or a BMI of 27 or above where at least one weight-related condition is present) such as high blood pressure, type 2 diabetes, high cholesterol or obstructive sleep apnoea. Tirzepatide is also separately licensed for type 2 diabetes management, though that indication is a different clinical context.

The NHS medicines page for tirzepatide covers the licensed uses, common side effects and key precautions in plain language. The medicine is not recommended during pregnancy, while breastfeeding, or for anyone trying to conceive. It is not licensed for under-18s. Certain medical histories, including a personal or family history of medullary thyroid carcinoma or a condition called MEN2, require careful prescriber assessment before any use.

A prescriber looks at far more than a single BMI number. Medical history, current medicines, previous weight-loss attempts and individual health goals all factor into the clinical review. Our clinical team reviews every consultation personally before any prescription is issued. If you want to understand the full eligibility picture, our Mounjaro overview covers what the assessment involves and what the process looks like in practice.